Colossal Biosciences Targets $20 Billion to $30 Billion Valuation in New Funding Round
Colossal Biosciences is pursuing a new funding round that could value the Dallas-based startup between $20 billion and $30 billion, according to reporting from TechCrunch. This represents a significant jump from a $10.2 billion valuation recorded in early 2025, effectively doubling or tripling the company’s estimated market value within a short window.
Revenue Diversification Beyond De-extinction
While Colossal is best known for its goal of bringing back extinct species, the company has begun to generate revenue. CEO Ben Lamm told TechCrunch that the firm now operates three primary revenue streams:
- Government Contracts: Colossal sells its conservation technology to national governments, including the United States and the United Arab Emirates. The UAE recently invested $60 million into the venture.
- Biodiversity Credits: The company plans to develop a market-based mechanism similar to carbon credits. These credits would be sold based on the successful reintroduction of species like the woolly mammoth or the dodo into their native habitats.
- Commercial Spin-offs: Colossal has launched three separate startups to monetize its core intellectual property. Form Bio, a computational biology platform, has raised $30 million. Astromech, which focuses on AI-driven predictive modeling for life sciences, reached a $2 billion valuation in March. Breaking focuses on developing biological solutions to degrade plastics.
Species Targets and Technological Milestones
Colossal has expanded its list of target species to six, adding the Blue Antelope in April. The company’s efforts extend beyond total de-extinction to active conservation. In May, the Colossal Foundation partnered with the University of Tasmania to protect Tasmanian devils from contagious facial tumor disease.
A critical piece of the company’s roadmap is the development of artificial womb technology. Ben Lamm announced in May that this technology is expected to be operational by next year. Lamm stated the technology could eventually be applied to human fertility treatments.
Market Context and Controversy
The surge in Colossal’s valuation aligns with a broader investment boom in “Deep Tech,” longevity science, and alternative energy. However, the company’s methods remain a point of scientific debate. Last year, Colossal faced criticism after announcing plans to “revive” the extinct dog species Aenocyon dirus using genetic material from fossils.
Despite these controversies, observers argue the company’s high valuation is supported by the development of valuable technologies.
| Metric | Early 2025 | Current Target |
|---|---|---|
| Company Valuation | $10.2 Billion | $20 Billion – $30 Billion |
| Target Species | Not specified | 6 (Added Blue Antelope) |
Frequently Asked Questions
What is the primary goal of Colossal Biosciences?
Colossal aims to bring back extinct species.
How does Colossal make money if the animals aren’t back yet?
According to CEO Ben Lamm, the company generates revenue by selling conservation technology to governments (like the UAE) and by spinning off specialized biotech firms focusing on AI and plastic degradation.
When will the artificial womb be ready?
Ben Lamm announced in May that the artificial womb technology is expected to be ready for use next year.
Keep reading